R T O'Neill

发表

FDA's critical path initiative: a perspective on contributions of biostatistics.

R T O'Neill, 2006, Biometrical journal. Biometrische Zeitschrift.

Competing risk analysis of life table data: application to lifetime risk computation.

M H Dong, R T O'Neill, S D Dubey, 1990, Journal of clinical epidemiology.

The behavior of the P-value when the alternative hypothesis is true.

R T O'Neill, P Bauer, R. O’Neill, 1997, Biometrics.

Secondary endpoints cannot be validly analyzed if the primary endpoint does not demonstrate clear statistical significance.

R T O'Neill, R. O’Neill, R. O'neill, 1997, Controlled clinical trials.

Discovery of adverse drug reactions. A comparison of selected phase IV studies with spontaneous reporting methods.

D E Knapp, R T O'Neill, C Anello, 1983, JAMA.

Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: linking quantitative risk assessment in pre-market licensure application safety data, post-market alert reports and formal epidemiological studies.

R T O'Neill, R. O’Neill, 1998, Statistics in medicine.

Efficacy evaluation for monotherapies in two-by-two factorial trials.

R T O'Neill, G Y Chi, H M Hung, 1995, Biometrics.

The Prevention and Treatment of Missing Data in Clinical Trials: An FDA Perspective on the Importance of Dealing With It

R T O'Neill, R. O’Neill, R. Temple, 2012, Clinical pharmacology and therapeutics.

Sample sizes for estimation of the odds ratio in unmatched case-control studies.

R T O'Neill, 1984, American journal of epidemiology.